Eribulin mesylate in pretreated breast cancer patients: A multicenter retrospective observational study

Journal of Cancer

Volumn 5, Issue 5, 2014, Pages 320-327

  Gamucci, Teresa ^a   Michelotti, Andrea ^b   Pizzuti, Laura ^c   Mentuccia, Lucia ^a   Landucci, Elisabetta ^b   Sperduti, Isabella ^c   Di Lauro, Luigi ^c   Fabi, Alessandra ^c   Tonini, Giuseppe ^d   Sini, Valentina ^e   Salesi, Nello ^f   Ferrarini, Ilaria ^b   Vaccaro, Angela ^a   Pavese, Ida ^g   Veltri, Enzo ^f   Moscetti, Luca ^h   Marchetti, Paolo ^e   Vici, Patrizia ^c  

^a ASL Frosinone   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f SANTA MARIA GORETTI HOSPITAL   (Italy)

^g FATEBENEFRATELLI HOSPITAL   (Italy)

^h BELCOLLE HOSPITAL   (Italy)

Author keywords

Advanced breast cancer; Chemotherapy; Eribulin mesylate; Heavily pretreated patients; Real world population

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERIBULIN; ESTROGEN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PREMEDICATION; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84896912550     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.8748     Document Type: Article

References (38)

1. El Saghir NS, Tfayli A, Hatoum HA, Nachef Z, Dinh P, Awada A. Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. Crit Rev Oncol Hematol. 2011; 80: 433-49
2. Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc. 2009; 84: 533-45
3. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005; 4: 1086-95
4. Smith JA, Wilson L, Azarenko O, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2010; 49: 1331-7
5. Towle MJ, Salvato KA, Wels BF, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011; 71: 496-505
6. Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010; 28: 3922-8.
7. Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2009; 27: 2954-61.
8. Aogi K, Iwata H, Masuda N, et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2012; 23: 1441-8.
9. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011; 377: 914-23.
10. Ayoub JP, Verma Sh, Verma S. Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy. Curr Oncol. 2012; 19: 91-105.
11. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol. 2008; 26: 4891-8.
12. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst. 2008; 100: 1780-91.
13. Gennari A, D'amico M, Corradengo D. Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review. Ther Adv Med Oncol. 2011; 3: 229-32.
14. Tacca O, LeHeurteur M, Durando X, et al. Metastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line? Cancer Invest. 2009; 27: 81-5.
15. Bernardo G, Palumbo R, Poggi G, et al. Beyond the second line chemotherapy in metastatic breast cancer: when stop the treatment between science and conscience. Cancer Res. 2010; 70 (Suppl 24): 446s.
16. Planchat E, Abrial C, Thivat E, et al. Late lines of treatment benefit survival in metastatic breast cancer in current practice? Breast. 2011; 20: 574-8.
17. Dufresne A, Pivot X, Tournigand C, et al. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008; 107: 275-9.
18. Palumbo R, Sottotetti F, Riccardi A, et al. Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians. Ther Adv Med Oncol. 2013; 5: 334-50.
19. Gradishar WJ. The place for eribulin in the treatment of metastatic breast cancer. Curr Oncol Rep. 2011; 13: 11-6.
20. Pusztai L, Hatzis C, Andre F. Reproducibility of research and preclinical validation: problems and solutions. Nat Rev Clin Oncol. 2013 Dec;10(12):720-4.
21. Korn EL, Freidlin B. Methodology for comparative effectiveness research: potential and limitations. J Clin Oncol. 2012; 30: 4185-7.
22. Vici P, Capomolla E, Foggi P, et al. High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients. J Exp Clin Cancer Res. 2006; 25: 39-44.
23. Vici P, Fabi A, Metro G, et al. Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. Cancer Chemother Pharmacol. 2011; 67: 687-93.
24. Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008; 26: 3950-7.
25. Pugliano L, de Azambuja E. Treatment options in anthracycline and/or taxane pretreated patients with metastatic breast cancer. Onkologie. 2012; 35: 476-8.
26. Vici P, Di Lauro L, Carpano S, et al. Vinorelbine and mitomycin C in anthracycline-pretreated patients with advanced breast cancer. Oncology. 1996; 53: 16-8.
27. Vici P, Di Lauro L, Sergi D, et al. A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines. Oncology. 2008; 75: 175-81.
28. Valero V, Hortobagyi GN. Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol. 2003; 21: 959-62.
29. Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2007; 7: 850-6.
30. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007; 25: 3399-406.
31. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007; 25: 3407-14.
32. Vahdat LT, Garcia AA, Vogel C, et al. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat. 2013; 140: 341-51.
33. Ershler WB. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist. 2006; 11: 325-35.
34. Blum JL, Barrios CH, Feldman N, et al. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2012; 136: 777-88.
35. Kaufman PA, Awada A, Twelves C, et al. A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Presented at: 2012 CTRC-AACR San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio, Texas. Abstract S6-6.
36. Poletti P, Ghilardi V, Livraghi L, Milesi L, Rota Caremoli E, Tondini C. Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital. Future Oncol. 2014; 10: 233-9.
37. Ramaswami R, O'Cathail SM, Brindley JH, Silcocks P, Mahmoud S, Palmieri C. Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund. Future Oncol. 2013; [Epub ahead of print].
38. Tinoco G, Warsch S, Glück S, Avancha K, Montero AJ. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer. 2013; 4: 117-32.